Potential withdrawal syndrome associated with SSRI discontinuation.
Lazowick
A L
AL
College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Miami 33136, USA.
Levin
G M
GM
D015057:1-Naphthylamine / Q000009:adverse effects / Q000031:analogs & derivatives; D016666:Fluvoxamine / Q000009:adverse effects*; D006801:Humans; D017374:Paroxetine / Q000009:adverse effects; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D020280:Sertraline; D013375:Substance Withdrawal Syndrome
D015057:1-Naphthylamine; D016666:Fluvoxamine; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline